RT @drteplinsky
10/22 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 8

🧐Does T-DXd work in all subgroups?
Analyses presented at #SABCS22
T-DXd is effective regardless of:
✅dz burden: ≥3 met sites
✅prior CDK 4/6i/rapid progress
✅HER2 IHC
✅prior chemo
✅age
✅base CNS mets
✅anthracycline use

RT @drteplinsky
11/22 #TumorBoardTuesday #BreastCancer #SABCS22
👩🏻‍🏫Mini tweetorial 9

🧐Does T-DXd work in all subgroups?

✅Safety profile consistent among subgroups
✅No differences in overall incidence of ILD observed

RT @drteplinsky
10/22 #TumorBoardTuesday
👩🏻‍🏫Mini tweetorial 8

🧐Does T-DXd work in all subgroups?
Analyses presented at #SABCS22
T-DXd is effective regardless of:
✅dz burden: ≥3 met sites
✅prior CDK 4/6i/rapid progress
✅HER2 IHC
✅prior chemo
✅age
✅base CNS mets
✅anthracycline use

RT @drteplinsky
11/22 #TumorBoardTuesday #BreastCancer #SABCS22
👩🏻‍🏫Mini tweetorial 9

🧐Does T-DXd work in all subgroups?

✅Safety profile consistent among subgroups
✅No differences in overall incidence of ILD observed

RT @GRASPtweets@twitter.com

Learn to refine treatment plans for patients with HR+/HER2- #BreastCancer by hearing expert recommendations by @ErikaHamilton9@twitter.com @DrWGradishar@twitter.com @hoperugo@twitter.com & Prof. Schmid. Produced by @PeerView@twitter.com w/ @GRASPtweets@twitter.com & @LivingBeyondBC@twitter.com https://bit.ly/3QN2Xmq #SABCS22 #BCSM #MedEd #MedTwitter

🐦🔗: https://twitter.com/GRASPtweets/status/1617547755672543233

Dr @StoverLab associate professor, is leading the OSU #BreastCancer #Translational Program, is the Vice Chair @ALLIANCE_org Breast Committee and was an invited discussant and panelist at #SABCS22 @OSUCCC_James @OSUWexMed

Dr @quirogad, Assistant Professor, graduated fellowship and started her new faculty position at OSU, received @ASCO CCF YIA, selected for Robert A Winn CDA and presented her work at #SABCS22 🧵3/11 #WomenInMedicine @OSUCCC_James @OSUWexMed #SSCBC

Dr Robert Wesolowski, Associate Professor, presented data from the Phase 1 Gedatolisib + Palbociclib + Endocrine Tx in #mBC with PIK3CA mutation at #SABCS22 #bcsm @OSUWexMed @OSUCCC_James He leads our Phase 1 efforts

RT @Sameh_VuMedi@twitter.com

Dr. Erika Hamilton @ErikaHamilton9@twitter.com @SarahCannonDocs@twitter.com discussing Dose-Expansion Study DESTINY-Breast07: T-DXd as Monotherapy or Combined With #Pertuzumab in pts With Metastatic #HER2+ #breastcancer from #SABCS22 #bcsm #mBC #VuMedi #OncTwitter #MedTwitter

https://bit.ly/SABCS22TDX

🐦🔗: https://twitter.com/Sameh_VuMedi/status/1605960936535117828

Was an honor to work with @DrWGradishar@twitter.com and @JWatch@twitter.com to cover #SABCS22

RT @JWatch@twitter.com

NEJM Journal Watch Oncology and Hematology reports on some of the key studies presented at the 2022 San Antonio Breast Cancer Symposium, with clinical perspective provided by Editor-in-Chief @DrWGradishar@twitter.com and guest author Dr. @ErikaHamilton9@twitter.com. https://jwat.ch/3FGQ0FD #SABCS22

🐦🔗: https://twitter.com/JWatch/status/1605927914205503493

RT @TumorBoardTues
#SABCS22 came & went, but the exciting info for #BreastCancer is continuing to come your way via #TumorBoardTuesday!!

@jane_meisel @quirogad
📅Tues, 12/20/22 at🕗8PM ET
✅polls
⚖️in & bring citations🧾
🔁Retweet & tag 🩺colleagues
🏆Earn your🆓CME & MOC http://integrityce.com/tbt

Long-term data in #GeparOLA trial demonstrated similar outcome when carboplatinum was exchanged by #Olaparib as part of the neoadjuvant chemotherapy when a #BRCA mutation was present but not in wt BRCA but HRD high tumor patients. #SABCS22
Full presentation: https://www.gbg.de/wAssets/docs/geparola/2022-SABCS_GeparOla-LongtimeFU.pdf

RT @TumorBoardTues
#SABCS22 came & went, but the exciting info for #BreastCancer is continuing to come your way via #TumorBoardTuesday!!

@jane_meisel @quirogad
📅Tues, 12/20/22 at🕗8PM ET
✅polls
⚖️in & bring citations🧾
🔁Retweet & tag 🩺colleagues
🏆Earn your🆓CME & MOC http://integrityce.com/tbt

RT @OncBrothers@twitter.com

1. #SABCS22 updates w/ @ErikaHamilton9@twitter.com from @SarahCannonDocs@twitter.com on Her 2 #breastcancer:

- #APT and #ATEMPT: de-escalating studies update
- #DestinyBreast 02, 03, and 04: TDxD in mBC updates

https://twitter.com/somecme/status/1604974908458549249?s=46&t=I28CdbeOrNmWP-sYMuaXgA

#bcsm #SABCSUpdate 
@OncoAlert@twitter.com @SoMeCME@twitter.com @SABCSSanAntonio@twitter.com

🐦🔗: https://twitter.com/OncBrothers/status/1604975479685251074

RT @TumorBoardTues
#SABCS22 came & went, but the exciting info for #BreastCancer is continuing to come your way via #TumorBoardTuesday!!

@jane_meisel @quirogad
📅Tues, 12/20/22 at🕗8PM ET
✅polls
⚖️in & bring citations🧾
🔁Retweet & tag 🩺colleagues
🏆Earn your🆓CME & MOC http://integrityce.com/tbt

#SABCS22 came & went, but the exciting info for #BreastCancer is continuing to come your way via #TumorBoardTuesday!!

@jane_meisel @quirogad
📅Tues, 12/20/22 at🕗8PM ET
✅polls
⚖️in & bring citations🧾
🔁Retweet & tag 🩺colleagues
🏆Earn your🆓CME & MOC http://integrityce.com/tbt

RT @JWatch@twitter.com

Joe Elia talks to @DrWGradishar@twitter.com and Dr. @ErikaHamilton9@twitter.com, our clinician-guides for this year's San Antonio Breast Cancer Symposium, about what they'll be bringing back to their patients. https://jwat.ch/3WpuNXN #SABCS22 #BreastCancer

🐦🔗: https://twitter.com/JWatch/status/1603790819701698561

RT @OncLive@twitter.com

.@ErikaHamilton9@twitter.com discusses anticipated updates from DESTINY-Breast02 and DESTINY-Breast03 from #SABCS22 and how trastuzumab emtansine will fit into the armamentarium in light of the efficacy of trastuzumab deruxtecan. @SABCSSanAntonio@twitter.com #bcsm http://ow.ly/74YM50M2auJ

🐦🔗: https://twitter.com/OncLive/status/1603253640034140160

This is a fantastic explanation of a complex topic from #SABCS22. Microbiome is certainly getting more and more exciting in the world of cancer care!

Thanks @amybeumer@twitter.com. Check out her blog, folks!

RT @amybeumer@twitter.com

Geeked out about the microbiome session at #SABCS22 so I wrote a blog post about some of it. You can check it out here if you are so inclined :-) Hoping to have part two (fungi!) up in a couple days. #bcsm https://roguecells.blogspot.com/2022/12/the-microbiome-at-sabcs-part-1.html

🐦🔗: https://twitter.com/amybeumer/status/1602115950828048385

Honestly, it's an honor to discuss #SABCS22 with all of you. 🥰

@Twitter@twitter.com has been a very welcome (and somewhat surprising!) way to immediately hear people's takes, thoughts, and concerns on new data real time!

#bcsm @OncoAlert@twitter.com